Processa Pharmaceuticals Doses First Patient in Amended Phase IB Protocol for PCS6422 Combined with Capecitabine (Next Generation Capecitabine)

Processa Pharmaceuticals, Inc. announced that the first patient with advanced, refractory gastrointestinal cancer has been dosed in its amended maximum tolerated dose Phase IB trial for Next Generation Capecitabine.